Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Monday, September 26, 2016 10:16:04 AM
http://redirect.viglink.com/?key=bbb516d91daee20498798694a42dd559&u=http%3A//www.aequuspharma.ca/investors/press-release/aequus-provides-corporate-update-on-commercial-and-development-programs
Once-Weekly Transdermal Aripiprazole
Patch Positive Proof of Concept Clinical Data for Once-Weekly Transdermal Aripiprazole Patch: Aequus’ once-weekly transdermal aripiprazole program is being developed for the treatment of certain psychiatric disorders. In the first half of 2016, Aequus announced positive results from an initial Proof of Concept clinical study, which suggested the current formulation may provide sustained, seven-day delivery of therapeutic doses of aripiprazole. Aequus is preparing for the follow-on, multi-dose bioavailability study expected to be initiated in the second half of 2016. Aequus has also expanded the patent portfolio for this program, with a patent issued / allowed in five major countries or regions, including the US, Russia, Mexico, Japan and Australia, and pending in multiple additional territories. Aequus owns worldwide rights to the formulation described in the issued patent, and will look to partner commercial rights in markets outside of Canada as the program continues to advance.
Long-Acting Transdermal Anti-Nausea Patch
Advancement of IP and Formulation Optimization for Long-Acting Transdermal Anti-Nausea Patch: Aequus is advancing a once-daily and up to a once-weekly transdermal doxylamine and pyridoxine combination patch for the treatment of nausea and vomiting in pregnancy (NVP). During the first half of 2016, the Company completed preclinical studies and expects to advance the current formulation into Proof of Concept clinical studies in the second half of 2016. Aequus has filed an international patent that covers the current formulation and has ownership of worldwide rights.
Aequus has been engaging with third parties around partnering discussions for each of its internal programs, with a goal of ensuring the maximum benefit is realized by shareholders.
---------------
Ian Ball – Former Global Head of Brand Maximization and Lifecycle Strategy with Novartis
?Strong relationships with key executives at Novartis and Sandoz
?Ability to structure low-upfront deals for valuable products
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM